Clinical characteristics of the asthma–COPD overlap syndrome–a systematic review
M Nielsen, CB Bårnes, CS Ulrik - International journal of chronic …, 2015 - Taylor & Francis
Background and objective In recent years, the so-called asthma–chronic obstructive
pulmonary disease (COPD) overlap syndrome (ACOS) has received much attention, not …
pulmonary disease (COPD) overlap syndrome (ACOS) has received much attention, not …
Advanced therapeutic strategies for chronic lung disease using nanoparticle-based drug delivery
JY Yhee, J Im, RS Nho - Journal of clinical medicine, 2016 - mdpi.com
Chronic lung diseases include a variety of obstinate and fatal diseases, including asthma,
chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), idiopathic pulmonary …
chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), idiopathic pulmonary …
Asthma–COPD overlap syndrome (ACOS): a diagnostic challenge
NV Tho, HY Park, Y Nakano - Respirology, 2016 - Wiley Online Library
Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is
characterized by persistent airflow limitation with several features usually associated with …
characterized by persistent airflow limitation with several features usually associated with …
Age-of-asthma onset as a determinant of different asthma phenotypes in adults: a systematic review and meta-analysis of the literature
Age-of-asthma onset is often used to distinguish different adult asthma phenotypes;
however, similarities and differences between early-and late-onset adult asthma have not …
however, similarities and differences between early-and late-onset adult asthma have not …
Volatile organic compounds in asthma diagnosis: a systematic review and meta‐analysis
J Cavaleiro Rufo, J Madureira, E Oliveira Fernandes… - Allergy, 2016 - Wiley Online Library
We aimed to assess the value and classification rate of exhaled volatile organic compounds
(VOC s) in asthma diagnosis. A PRISMA‐oriented systematic search for published studies …
(VOC s) in asthma diagnosis. A PRISMA‐oriented systematic search for published studies …
Pharmacological strategies to reduce exacerbation risk in COPD: a narrative review
M Miravitlles, A D'Urzo, D Singh, V Koblizek - Respiratory research, 2016 - Springer
Identifying patients at risk of exacerbations and managing them appropriately to reduce this
risk represents an important clinical challenge. Numerous treatments have been assessed …
risk represents an important clinical challenge. Numerous treatments have been assessed …
New therapeutic targets for the prevention of infectious acute exacerbations of COPD: role of epithelial adhesion molecules and inflammatory pathways
Chronic respiratory diseases are among the leading causes of mortality worldwide, with the
major contributor, chronic obstructive pulmonary disease (COPD) accounting for …
major contributor, chronic obstructive pulmonary disease (COPD) accounting for …
Bronchodilating drugs for chronic obstructive pulmonary disease: current status and future trends
P Montuschi, G Ciabattoni - Journal of medicinal chemistry, 2015 - ACS Publications
Inhaled bronchodilators, including long-acting muscarinic receptor antagonists (LAMA) and
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
long-acting β2-adrenoreceptor agonists (LABA), are the mainstay of pharmacological …
Electronic nose and exhaled breath NMR-based metabolomics applications in airways disease
G Santini, N Mores, A Penas… - Current topics in …, 2016 - ingentaconnect.com
Breathomics, the multidimensional molecular analysis of exhaled breath, includes analysis
of exhaled breath with gas-chromatography/mass spectrometry (GC/MS) and electronic …
of exhaled breath with gas-chromatography/mass spectrometry (GC/MS) and electronic …
Review of drug development guidance to treat chronic obstructive pulmonary disease: US and EU perspectives
A van Haarst, L McGarvey… - Clinical Pharmacology & …, 2019 - Wiley Online Library
Chronic obstructive pulmonary disease (COPD) remains a leading cause of death
worldwide, yet only one new drug class has been approved in the last decade. However …
worldwide, yet only one new drug class has been approved in the last decade. However …